Prosecution Insights
Last updated: April 19, 2026

Cemm - Forschungszentrum Für Molekulare Medizin GmbH

5 pending office actions

Portfolio Summary

5
Total Pending OAs
0
Final Rejections
5
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18562029 1,2,4-TRIAZOLO[1,5-A]PYRIMIDINE-BASED SLC16A3 INHIBITORS AND THEIR THERAPEUTIC USE HAVLIN, ROBERT H 1626 Non-Final OA Nov 17, 2023
17641048 METHOD FOR SEQUENCING RNA OLIGONUCLEOTIDES CASH, KAILEY ELIZABETH 1683 Non-Final OA Sep 08, 2022
17778927 NOVEL METHOD FOR POOLED INTRON TAGGING FOR REAL TIME DRUG SCREENING CHOWDHURY, IQBAL HOSSAIN 1656 Non-Final OA May 23, 2022
17769323 COMPOUNDS FOR TARGETED DEGRADATION OF CARRIER PROTEINS AND USES THEREOF RAO, PADMAJA S 1627 Non-Final OA Apr 14, 2022
17673686 MUTANT CALRETICULIN FOR THE DIAGNOSIS OF MYELOID MALIGNANCIES AEDER, SEAN E 1642 Non-Final OA Feb 16, 2022

Managing Cemm - Forschungszentrum Für Molekulare Medizin GmbH's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month